Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Metastatic Melanoma
100%
Ipilimumab
100%
Nivolumab
100%
Real-world Outcomes
100%
Nave
75%
Adverse Events
75%
Patient Characteristics
50%
Response Rate
50%
Real-world Population
50%
Melanoma
25%
Clinical Trials
25%
Treatment Outcome
25%
Median Overall Survival
25%
Overall Survival
25%
Survival Outcomes
25%
Medical Records
25%
Prognostic Factors
25%
Treatment Discontinuation
25%
Histology
25%
Single Center
25%
Lactate Dehydrogenase
25%
Efficacy Outcomes
25%
Steroid Treatment
25%
Treatment Characteristics
25%
Tumor Survival
25%
Melanoma Patients
25%
Oncologic
25%
Median Progression-free Survival
25%
Tumor Response
25%
Performance Status
25%
Induction Period
25%
Online Treatment
25%
Dual Blockade
25%
Site-specific Performance
25%
Toxicity Outcomes
25%
Previously Treated Patients
25%
Immune Checkpoint
25%
Treatment Line
25%
Information Response
25%
Number of Metastatic Sites
25%
Medicine and Dentistry
Metastatic Melanoma
100%
Nivolumab
100%
Ipilimumab
100%
Adverse Event
75%
Nodular Melanoma
50%
Overall Survival
50%
Neoplasm
25%
Clinical Trial
25%
Patient Characteristics
25%
Progression Free Survival
25%
Prognostic Factor
25%
Medical Record
25%
Lactate Dehydrogenase
25%
Steroid Treatment
25%
Immunotherapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Melanoma
100%
Nivolumab
100%
Ipilimumab
100%
Adverse Event
75%
Melanoma
50%
Overall Survival
50%
Clinical Trial
25%
Steroid Treatment
25%
Progression Free Survival
25%
Neoplasm
25%
Immunotherapy
25%
Lactate Dehydrogenase
25%